DNA vaccine VGX-3100 with electroporation induces regression of cervical intraepithelial neoplasia 2/3 and clears HPV infection with robust T cell responses: results of a randomized, double-blind, placebo-controlled Phase II trial

Podobne knjige/članki

• Augmentation of cellular and humoral immune responses to HPV16 and HPV18 E6 and E7 antigens by VGX-3100
  od: Morrow, Matthew P, et al.
  Izdano: (2016)
• Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial
  od: Trimble, Cornelia L, et al.
  Izdano: (2015)
• Safety and immunogenicity of VGX-3100 formulations in a healthy young adult population
  od: Hollenberg, Rebecca K., et al.
  Izdano: (2019)
• Durability of response to VGX-3100 treatment of HPV16/18 positive cervical HSIL
  od: Bhuyan, Prakash K., et al.
  Izdano: (2020)
• Immunotherapy with VGX-3100 (HPV16 and HPV18 plasmids) + INO-9012 (DNA encoding IL-12) in human papillomavirus (HPV) associated head and neck squamous cell carcinoma (HNSCCa): interim safety and immunogenicity results
  od: Aggarwal, Charu, et al.
  Izdano: (2015)